GLP-2 (HUMAN)

Description

GLP-2 is cosecreted with GLP-1 in response to nutrient ingestion. The principal role of GLP-2 appears to be the maintenance of the growth and absorptive function of the intestinal mucosal villus epithelium. GLP-2 was first identified as a novel peptide following the cloning of the proglucagon gene in the early 1980s, and subsequently the biosynthesis and release of GLP-2 were confirmed by isolation and characterization from the porcine and human small intestine. The biological role of GLP-2 as a stimulator of intestinal epithelial proliferation was first demonstrated in 1996.

Clinical Use

The pharmacological application of GLP-2 has been recognized and assessed in preclinical and clinical investigations to prevent or treat a number of intestinal diseases, including short bowel syndrome, Crohn’s disease, inflammatory bowel disease, chemotherapyinduced intestinal mucositis, colon carcinogenesis, and small bowel enteritis. The US Food and Drug Administration has accepted Teduglutide, an analog of GLP-2, for use in adult patients with short bowel syndrome.

Storage

Store at -20°C